Sempre Health presents a compelling case for a healthcare technology platform that addresses the inefficiency of the $4 billion annual spend on pharmaceutical coupons. By positioning themselves as a two-sided marketplace, they connect pharmaceutical brands with payors to drive medication adherence through dynamic, SMS-based pricing. The deck excels at demonstrating clinical and behavioral outcomes, such as a 92% activation rate and a significant reduction in unplanned care (from 28% in a control group to 20% for Sempre members). While the deck is strong on product-market fit and impact, it la…
Key takeaways
- The company targets a $4 billion annual spend on drug coupons that currently suffers from a lack of payor visibility and unsophisticated targeting (Slide 2).
- Sempre operates a two-sided marketplace that matches brand budgets with payor demand to provide personalized patient benefits for free to the payor (Slide 3).
- The platform uses proprietary technology to ingest payor data and drive adherence via SMS-based dynamic discounts at any pharmacy (Slide 3).
- Geographic reach is significant, with a map showing active payor partnerships across the majority of the United States (Slide 4).
- Engagement metrics are high, claiming 8x higher enrollment than typical payor programs and a 92% activation rate for enrolled members (Slide 5).
- Clinical outcomes show a reduction in unplanned care from 28% to 20% and a reduction in ED admissions from 20% to 13% compared to a control group (Slide 6).
- The business model relies on charging only those who have the most to gain immediately, while optimizing for adoption from others (Slide 7).
- Future expansion opportunities include Specialty drugs ($406B spend), Generics ($140B), and Medicare Part D ($129B) (Slide 8).
Slide-by-Slide Teardown
Slide 1: Title Slide
The deck opens with a clean, minimalist title slide featuring the Sempre Health logo and a high-quality photograph of an older man using a smartphone. This immediately signals the target demographic (seniors or those managing chronic conditions) and the primary interface (mobile technology). There is no tagline or mission statement on this slide, relying entirely on visual cues to set the stage.
Slide 2: The Problem
This slide identifies a massive inefficiency in the pharmaceutical market. It states there is "$4B Annual spend on drug coupons" but notes these dollars are "not spent well." The slide lists four specific pain points: lack of payor visibility and control, unsophisticated targeting and economics, a 'one size fits all' approach with little power to incentivize, and increasing regulatory scrutiny. A chart shows the average patient cost-sharing and manufacturer buy-down per prescription from 2013 to 2017, illustrating the volatility and complexity of drug pricing.
Slide 3: The Solution and Process
Sempre introduces its three-step process for leveraging manufacturer dollars to improve adherence. Step 1: A two-sided marketplace matches brand budgets to payor demand. Step 2: Proprietary technology ingests payor data and uses pricing algorithms to drive adherence via "SMS + dynamic discounts." Step 3: Partners see statistically significant improvements in adherence and downstream outcomes. A key takeaway here is the claim that they provide this benefit to payors "for free."
Slide 4: Market Traction
To demonstrate scale, Slide 4 features a map of the United States with a majority of states shaded in blue, indicating payor coverage. The sidebar reinforces the value to payor partners: improved affordability, differentiated member offerings, conversational SMS engagement, real-time data, and support for existing formularies. The repetition of the word "Free" at the bottom of the list emphasizes their disruptive business model for the payor side of the marketplace.
Slide 5: Enrollment and Activation Metrics
This is a high-impact data slide. It claims "8x higher enrollment than typical payor programs." The specific metrics are 35% Enrolled (members who submitted a phone number and consented) and 92% Activated (members who filled at least one prescription with Sempre). A donut chart shows that 60% of enrollment comes via SMS, 21% via phone/email, and 19% via a landing page, suggesting that their mobile-first approach is the primary driver of growth.
Slide 6: Clinical Outcomes
Sempre moves from engagement metrics to clinical validity. A bar chart compares a control group to Sempre members across three categories: ED admissions (20% vs 13%), Observation admissions (5% vs 2%), and All unplanned care (28% vs 20%). The slide also includes a testimonial from 'Judy Miller' in Illinois, who credits the program with helping her lose 25 pounds and drop her fasting blood sugar from 145 to 100. This combination of hard data and human narrative is a classic, effective pitch technique.
Slide 7: Incentive Alignment
This slide explains the philosophy behind the business model. It outlines four pillars: creating immediate-term benefits for patients, steering patients toward good decision-making rather than treating them like 'consumers,' creating a product patients 'can't live without,' and a revenue model that "charges only those who have the most to gain immediately." This implies that while payors get the service for free, the pharmaceutical manufacturers (who gain from increased volume and adherence) are the likely source of revenue.
Slide 8: Future Opportunities
The final slide in the sequence looks at the Total Addressable Market (TAM) expansion. It lists four massive verticals: Specialty ($406B annual spend), Generics ($140B annual spend), Medicare ($129B annual Part D spend), and POS rebates ($76B). By citing these figures, Sempre is signaling that their current focus on brand-name drug coupons is just the entry point into a much larger ecosystem of healthcare spend management.
What Works Well
Clear Value Proposition: The deck does an excellent job of explaining a complex three-way relationship between patients, payors, and manufacturers. By stating that the service is free for payors, they remove a significant barrier to entry for one side of their marketplace.
Strong Data Points: The jump from 35% enrollment to 92% activation is a powerful indicator of product stickiness. Furthermore, the clinical data regarding the reduction in unplanned care (28% to 20%) provides the 'why' for payors to integrate the platform, even if it were not free.
Focus on Frictionless UX: The emphasis on SMS as the primary driver of enrollment (60%) shows an understanding of patient behavior. In healthcare, high-friction apps often fail; Sempre’s reliance on simple text messaging is a strategic advantage highlighted well in the deck.
What Is Missing
The Team Slide: In the provided sequence, there is no mention of the founders or the leadership team. In healthcare technology, regulatory and industry expertise is paramount. Investors need to know who is navigating the complex legal landscape of drug rebates and HIPAA compliance.
Competitive Landscape: The deck identifies the problem with traditional coupons but does not mention other startups or legacy players (like GoodRx or PBM-owned programs) that might be competing for the same patient attention or manufacturer budgets.
Financials and The Ask: There are no slides detailing current revenue, burn rate, or the specific amount of capital being raised. Without a 'Use of Funds' slide, the deck functions more as a sales presentation than a complete fundraising tool.
What a Founder Should Copy
The 'Headline' Strategy: Every slide in this deck uses a full sentence as a headline that summarizes the main takeaway (e.g., "We see 8x higher enrollment than typical payor programs"). This allows a skimmer to understand the entire narrative without reading the smaller text.
Visualizing the 'Two-Sided Marketplace': Slide 3 uses a simple graphic to show how the company sits in the middle of supply and demand. Founders building marketplace businesses should emulate this simplicity to avoid over-complicating their role in the value chain.
Outcome-Oriented Metrics: Instead of just focusing on 'users,' Sempre focuses on 'Activation' and 'Unplanned Care Reduction.' Founders should always prioritize metrics that prove their product solves the core problem they identified at the start of the deck.
Frequently asked questions
- What is the core problem Sempre Health is solving?
- Sempre Health addresses the inefficiency of the $4 billion spent annually on pharmaceutical coupons. According to Slide 2, these coupons suffer from a lack of payor visibility, 'one size fits all' pricing that fails to incentivize behavior, and increasing regulatory scrutiny. By fixing these inefficiencies, they aim to improve medication adherence, which is traditionally low in standard payor programs.
- How does the Sempre Health technology work for the patient?
- The patient experience is centered on SMS engagement. As shown on Slide 3, the platform sends text messages to patients notifying them that their prescription is ready and offering a dynamic discount (e.g., 'Usually it's $30, next month it's $10'). This creates a 'personalized patient benefit over time' that rewards adherence with lower out-of-pocket costs at any pharmacy in the country.
- What are the primary benefits for healthcare payors?
- Payors receive the service 'for free' (Slide 3). The value proposition for them includes improved member affordability and adherence, a differentiated member offering, and access to real-time, real-world data (Slide 4). Most importantly, it supports their existing formulary while reducing downstream costs associated with non-adherence, such as emergency department visits.
- Does the deck provide evidence of clinical impact?
- Yes, Slide 6 provides specific data comparing Sempre members to a control group. It shows that Sempre members had lower rates of Emergency Department (ED) admissions (13% vs 20%), lower observation admissions (2% vs 5%), and a lower overall rate of unplanned care (20% vs 28%). The slide also includes a qualitative testimonial regarding weight loss and blood sugar reduction.
- What is missing from this pitch deck?
- The provided eight slides lack several critical components of a standard venture pitch. There is no team slide highlighting the founders' expertise, no competition slide, no detailed financial model or revenue projections, and no slide detailing the specific investment 'ask' or use of funds. These omissions make it difficult to evaluate the investment opportunity beyond the product's utility.
